BRPI0718850A2 - METHODS OF TREATING, DIAGNOSING OR DETECTION CANCER - Google Patents
METHODS OF TREATING, DIAGNOSING OR DETECTION CANCERInfo
- Publication number
- BRPI0718850A2 BRPI0718850A2 BRPI0718850-1A2A BRPI0718850A BRPI0718850A2 BR PI0718850 A2 BRPI0718850 A2 BR PI0718850A2 BR PI0718850 A BRPI0718850 A BR PI0718850A BR PI0718850 A2 BRPI0718850 A2 BR PI0718850A2
- Authority
- BR
- Brazil
- Prior art keywords
- diagnosing
- treating
- methods
- detection cancer
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G01N33/575—
-
- G01N33/5758—
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85888206P | 2006-11-14 | 2006-11-14 | |
| PCT/US2007/084293 WO2008061020A2 (en) | 2006-11-14 | 2007-11-09 | Methods of treating, diagnosing or detecting cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0718850A2 true BRPI0718850A2 (en) | 2014-02-25 |
Family
ID=39402414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0718850-1A2A BRPI0718850A2 (en) | 2006-11-14 | 2007-11-09 | METHODS OF TREATING, DIAGNOSING OR DETECTION CANCER |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2084540A2 (en) |
| JP (1) | JP2010509368A (en) |
| KR (1) | KR20090080082A (en) |
| CN (1) | CN101558308A (en) |
| AU (1) | AU2007319360A1 (en) |
| BR (1) | BRPI0718850A2 (en) |
| CA (1) | CA2668714A1 (en) |
| MX (1) | MX2009005058A (en) |
| WO (1) | WO2008061020A2 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| EP2511298B1 (en) | 2005-10-31 | 2019-01-16 | Oncomed Pharmaceuticals, Inc. | Compositions and Methods for Treating Cancer based on human FZD receptors |
| BRPI0919473A2 (en) | 2008-09-26 | 2017-08-29 | Oncomed Pharm Inc | FRIZZLED BINDING AGENTS AND THEIR USES |
| TWI535445B (en) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt antagonists and methods of treatment and screening |
| NZ602700A (en) | 2010-04-01 | 2014-10-31 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
| JP6355555B2 (en) | 2011-04-01 | 2018-07-11 | キアゲン | Gene expression signature for WNT / B-catenin signaling pathway and use thereof |
| EP3783028A1 (en) * | 2011-08-12 | 2021-02-24 | Omeros Corporation | Anti-fzd10 monoclonal antibodies and methods for their use |
| WO2013157410A1 (en) * | 2012-04-17 | 2013-10-24 | Hoya株式会社 | Fzd10-binding peptide |
| JP2015536933A (en) | 2012-10-23 | 2015-12-24 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Methods of treating neuroendocrine tumors using Wnt pathway binding agents |
| CN103048446B (en) * | 2012-12-25 | 2015-02-04 | 苏州浩欧博生物医药有限公司 | Luteinizing hormone nano-magnetic particle chemiluminescence assay kit and preparation method thereof and assay method thereof |
| AU2014212081A1 (en) | 2013-02-04 | 2015-08-13 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| US9863953B2 (en) * | 2013-05-16 | 2018-01-09 | Kyoto University | Method for determining prognosis of cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004020668A2 (en) * | 2002-08-30 | 2004-03-11 | Oncotherapy Science, Inc. | Method for treating synovial sarcoma |
| ATE545658T1 (en) * | 2003-07-11 | 2012-03-15 | Oncotherapy Science Inc | METHOD FOR TREATING SYNOVIAL SARCOMA |
| US8221751B2 (en) * | 2006-06-21 | 2012-07-17 | Oncotherapy Science, Inc. | Tumor-targeting monoclonal antibodies to FZD10 and uses thereof |
-
2007
- 2007-11-09 BR BRPI0718850-1A2A patent/BRPI0718850A2/en not_active Application Discontinuation
- 2007-11-09 KR KR1020097009781A patent/KR20090080082A/en not_active Withdrawn
- 2007-11-09 WO PCT/US2007/084293 patent/WO2008061020A2/en not_active Ceased
- 2007-11-09 MX MX2009005058A patent/MX2009005058A/en not_active Application Discontinuation
- 2007-11-09 EP EP07871425A patent/EP2084540A2/en not_active Withdrawn
- 2007-11-09 CN CNA2007800421795A patent/CN101558308A/en active Pending
- 2007-11-09 AU AU2007319360A patent/AU2007319360A1/en not_active Abandoned
- 2007-11-09 CA CA002668714A patent/CA2668714A1/en not_active Abandoned
- 2007-11-09 JP JP2009536514A patent/JP2010509368A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008061020A3 (en) | 2008-08-07 |
| MX2009005058A (en) | 2009-05-25 |
| KR20090080082A (en) | 2009-07-23 |
| CA2668714A1 (en) | 2008-05-22 |
| JP2010509368A (en) | 2010-03-25 |
| EP2084540A2 (en) | 2009-08-05 |
| CN101558308A (en) | 2009-10-14 |
| WO2008061020A9 (en) | 2008-11-13 |
| AU2007319360A1 (en) | 2008-05-22 |
| WO2008061020A2 (en) | 2008-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0718850A2 (en) | METHODS OF TREATING, DIAGNOSING OR DETECTION CANCER | |
| BRPI0809137A2 (en) | methods of diagnosing, endometrial cancer and precancer classify and treat | |
| ZA200808669B (en) | Methods of treating, diagnosing or detecting cancer | |
| EP2019675A4 (en) | METHODS FOR TREATING OR PREVENTING NEOPLASIA | |
| CR10667A (en) | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER | |
| BRPI0810206A2 (en) | CANCER TREATMENT METHOD | |
| WO2010017515A3 (en) | Breast cancer specific markers and methods of use | |
| BRPI0815588A2 (en) | POLYORGANOSYLOXAN-POLYURERIA AND / OR POLYORGANOSYL-XANO-POLYURETHANE COMPOUNDS | |
| IL197217B (en) | New antibodies against 38cd for cancer treatment | |
| BRPI0813364A2 (en) | DIAGNOSTIC METHODS AND CANCER TREATMENT. | |
| BRPI0920104A2 (en) | solution or wastewater treatment | |
| BRPI0719202A2 (en) | Diagnosis and treatment of cancer using antiereg antibody | |
| BR112013000745A2 (en) | "Method for diagnosing or detecting colorectal cancer in an individual, treatment method and method for monitoring the effectiveness of colorectal cancer treatment in an individual" | |
| BRPI0715763A2 (en) | treating or preventing cancers by overexpressing reg4 or kiaa0101 | |
| IL196470A (en) | Antagonist antibody for cancer treatment | |
| BRPI0814307A2 (en) | PRESBIOPIC TREATMENT SYSTEM | |
| PL2733492T3 (en) | Method of cancer detection | |
| PT2115472E (en) | CANCER BIOMARCATORS | |
| BRPI0811775A2 (en) | POLYCARBONATE COMPOUNDS-AND / OR POLYURETHANE-POLYORGANOSILOXANE | |
| EP2024509A4 (en) | DETECTION METHOD | |
| EP2047622A4 (en) | SPATIAL SPECTRAL DETECTION OF FAKE FINGERPRINTS | |
| EP2087201A4 (en) | SUBMARINE TREATMENT SYSTEM | |
| BRPI0814849A2 (en) | COMPACT WASH GUT SYSTEM | |
| EP2281903A4 (en) | CANCER MARKER, CANCER EVALUATION METHOD USING THE CANCER MARKER AND EVALUATION REAGENT | |
| EP2191453A4 (en) | VEHICLE DETECTION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |